Loading
A phase 2 trial of Mecapegfilgrastim and Dalpiciclib in Breast cancer, run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, active and no longer recruiting.
Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer is a phase 2 interventional study registered as NCT05463601 by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, with 132 participants planned, started 2022-08-01 and due to reach its primary completion in 2025-01-31. Interventions recorded: Mecapegfilgrastim, dalpiciclib, exemestane, fulvestrant, letrozole, tamoxifen. Conditions recorded: Metastatic Breast Cancer.
Linked to the drug Mecapegfilgrastim because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Mecapegfilgrastim and the tag pipeline.
Shares Dalpiciclib and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/